Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD3/anti-GUCY2C bispecific antibody PF-07062119

A bispecific antibody against human CD3, a T-cell surface antigen, and human guanylate cyclase 2C (GUCY2C; GCC; guanylyl cyclase C; heat-stable enterotoxin receptor; hSTAR), with potential antineoplastic activity. Upon administration, anti-CD3/anti-GUCY2C bispecific antibody PF-07062119 targets and binds to both CD3 on T cells and GUCY2C expressed on certain tumor cells. This results in the cross-linking of T cells and tumor cells, and induces a cytotoxic T-lymphocyte (CTL) response against GUCY2C-expressing tumor cells. GUCY2C, a transmembrane receptor expressed on intestinal epithelial cells, is overexpressed on certain tumors of the gastrointestinal (GI) tract.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD3 x anti-GUCY2C bispecific antibody PF-07062119
anti-GUCY2C/anti-CD3 bispecific antibody PF-07062119
T-cell bispecific antibody PF-07062119
Code name:PF 07062119
PF-07062119
PF07062119
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search